Guidant Holds To 2005 Drug-Eluting Stent E.T.A. Despite Trial Delay

The start of Guidant's SPIRIT FIRST dose-selection clinical trial for the everolimus-eluting Vision stent will be delayed three to six months due to foreign-body responses detected in pre-clinical studies